Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in Multiple Sclerosis

NCT05779449 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.

NCT NCT05779449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in Multiple Sclerosis
Lead sponsor
Neuromed IRCCS
Phase
Not applicable
Overall status
Unknown status
Start date
July 26, 2023
Completion date
May 1, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patient participation